clinical trial · NCT07358546
A Study of Efimosfermin Alfa in Adults With Hepatic Impairment
Non-alcoholic Fatty Liver DiseaseEfimosfermin alfa
brief summary
This study is designed to study the pharmacokinetic (PK) and safety profiles of a single dose of efimosfermin alfa in participants with varying degrees of Hepatic Impairment (HI) (assessed by Child-Pugh score) due to steatotic liver disease, with and without significant alcohol consumption.
started
Mar 13, 2026
primary completion
Oct 13, 2027
completion
Oct 13, 2027
last updated
Jun 9, 2026
official title
A Phase 1, Open-label, Single-dose Study to Evaluate the Pharmacokinetics and Safety of Efimosfermin Alfa in Adults With Varying Degrees of Hepatic Impairment Due to Steatotic Liver Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol